<div id="readability-page-1"><p>Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) will likely be posting its  Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Kyverna Therapeutics to post earnings of ($0.75) per share for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.</p><div><p><span></span><span>Get <strong>Kyverna Therapeutics</strong> alerts:</span></p></div><p>Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Thursday, March 26th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.80).  On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year. </p><h2>Kyverna Therapeutics Price Performance</h2><p>NASDAQ:KYTX traded up $0.12 during midday trading on Tuesday, hitting $9.12. The company had a trading volume of 357,783 shares, compared to its average volume of 867,113. Kyverna Therapeutics has a 52-week low of $1.92 and a 52-week high of $13.67. The stock's fifty day moving average price is $8.73 and its 200-day moving average price is $8.21. The company has a market capitalization of $552.03 million, a PE ratio of -2.50 and a beta of 2.05. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research analysts recently issued reports on KYTX shares. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. HC Wainwright  reaffirmed a &#34;buy&#34; rating and issued a $20.00 target price on shares of Kyverna Therapeutics in a research note on Thursday, April 23rd. Finally, Wall Street Zen lowered Kyverna Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, March 21st. Four research analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.67.</p><p><b>Read Our Latest Stock Report on KYTX</b></p><h2>Institutional Trading of Kyverna Therapeutics</h2><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new stake in  Kyverna Therapeutics in the third quarter worth $28,000.  EntryPoint Capital LLC purchased a new position in shares of  Kyverna Therapeutics in the 4th quarter worth about $94,000.  Ameriprise Financial Inc. purchased a new position in shares of  Kyverna Therapeutics in the 3rd quarter worth about $77,000.  Qube Research &amp; Technologies Ltd purchased a new position in  Kyverna Therapeutics in the 2nd quarter worth approximately $43,000.  Finally, Jefferies Financial Group Inc. purchased a new position in  Kyverna Therapeutics in the 3rd quarter worth approximately $98,000. Hedge funds and other institutional investors own  18.08% of the company's stock. </p><h2>About Kyverna Therapeutics</h2> (Get Free Report)<p>Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.  </p><p>The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.</p><h2>Read More</h2><ul><li>Five stocks we like better than Kyverna Therapeutics</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kyverna Therapeutics Right Now?</h2><p>Before you consider Kyverna Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.</p><p>While Kyverna Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KYTX

IBBQ

LABU

SBIO

<p>Kyverna Therapeutics (NASDAQ:KYTX) is set to release its Q1 2026 earnings on May 12, with analysts expecting a loss of $0.75 per share. The company previously reported a loss of $0.80 per share for Q1 2025. KYTX shares recently traded at $9.12, with a market cap of $552.03 million. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $28.67. Institutional investors hold 18.08% of the stock, and the company focuses on engineered T-cell therapies for autoimmune diseases.</p>

Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday